ESMO: European Society for Medical Oncology

1. FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection Products

   Additional safety information regarding the risk of serious adverse reactions related to fluorouracil use in patients with DPD deficiency became available since its approval

2. Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive Stage IB, II, or IIIA NSCLC

   Findings from the ALINA study

3. Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly Improves the pCR in Locally Advanced Vulvar Squamous Cell Carcinoma

   Findings from the NRG Oncology/GOG Study 279

4. EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab

   Wyost is highly similar to the reference product Xgeva which was authorised in the EU in 2011

5. A Novel Model Helps Better Predict Risk of Cancer Development in Patients with Li-Fraumeni Syndrome

   Better risk counselling may be achieved using the mathematical model